{
    "clinical_study": {
        "@rank": "73738", 
        "arm_group": [
            {
                "arm_group_label": "Dexmedetomidine infusion", 
                "arm_group_type": "Experimental", 
                "description": "Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the effect of dexmedetomidine infusion on the\n      Apnea / Hypopnea Index (AHI) of individuals with previously documented obstructive sleep\n      apnea. We hypothesize that dexmedetomidine infusion may reduce the AHI in patients with\n      obstructive sleep apnea (OSA)."
        }, 
        "brief_title": "Sedative Effects in Obstructive Sleep Apnea", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obstructive Sleep Apnea", 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All individuals who have previously undergone diagnostic polysomnography in the Sleep\n             Lab which documented significant OSA, and who have not undergone any changes that are\n             likely to alter the severity of their condition since the time of their diagnostic\n             sleep study (loss of weight; surgical therapy for OSA; removal of tonsils;\n             discontinuation of medications likely to affect arousal or respiratory function,\n             etc.) are eligible to participate. Subjects will be identified as they complete\n             outpatient sleep studies or from records of previous sleep studies performed in the\n             Duke Sleep Laboratory. After obtaining informed consent, subjects will be screened by\n             history and physical examination, 12-lead electrocardiogram, and comprehensive\n             metabolic profile.\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria will include a history of illicit drug or alcohol dependence,\n             impaired hepatic (aspartate aminotransferase or alanine aminotransferase > 2x upper\n             limit of normal range) or renal function (receiving dialysis or serum creatinine >\n             1.5 mg/dL), high-grade (> 1st degree) heart block, or known allergy to\n             dexmedetomidine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733043", 
            "org_study_id": "Pro00033021"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexmedetomidine infusion", 
                "intervention_name": "Dexmedetomidine", 
                "intervention_type": "Drug", 
                "other_name": "Precedex"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "Dexmedetomidine for Sedation in Individuals With Obstructive Sleep Apnea", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Brian Colin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is frequency of apnea or hypopnea as measured by the apnea hypopnea index", 
            "measure": "Apnea Hypopnea Index", 
            "safety_issue": "No", 
            "time_frame": "8 hour sleep study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733043"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Additional measures of sleep architecture will be made: sleep onset latency, duration of time spent in rapid eye movement (REM) and non-rapid eye movement (NREM) sleep, sleep efficiency, and number of arousals", 
            "measure": "Sleep Architecture", 
            "safety_issue": "No", 
            "time_frame": "During 8 hour sleep study"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}